Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 398 results for "Ibrutinib"

Idelalisib in Second-Line Treatment for Chronic Lymphocytic Leukemia

Seasonal Influenza Vaccination in Patients With Chronic Lympho...

Also Meets CME requirements for: Browse CME for all U.S. States The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA ... Journal of the American Medical Association, 2 weeks ago

19 images for Ibrutinib

Irish Examiner, 2 weeks ago, 1 month ago
Targeted Oncology, 2 months ago
Pharmafile, 2 months ago
Cancer Therapy Advisor, 2 months ago
Nasdaq, 2 months ago
Pharmafile, 3 months ago
Cancer Therapy Advisor, 4 months ago
Irish Medical Times, 4 months ago
OncLive, 4 months ago

Pending EC decision: Imbruvica, ibrutinib, Opinion date: 21-Jul-2016

the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Imbruvica. The marketing authorisation holder for this medicinal product ...
 European Medicines Agency1 month ago

Ibrutinib Receives Orphan Drug and Breakthrough Therapy Designation for cGVHD

FDA granted Imbruvica (ibrutinib) Breakthrough Therapy designation and Orphan Drug designation as a monotherapy for the treatment of patients with chronic graft-versus-host-disease (cGVHD) after failure or one more lines of systematic therapy. This ...
 PharmTech.com1 month ago
European Pharmaceutical Review

Ibrutinib Granted Breakthrough Therapy Designation for cGVHD Treatment

Oncology Times: doi: 10.1097/01.COT.0000490069.83486.2f FDA Updates The FDA has granted a fourth breakthrough therapy designation (BTD) for ibrutinib (Imbruvica) as monotherapy for the treatment of patients with chronic ...
 Oncology Times3 weeks ago Ibrutinib IMBRUVICA Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration FDA for the Development of a Treatment for Chronic...  Pharmacy Choice1 month ago Ibrutinib IMBRUVICA® Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration FDA for the Development of a Treatment for Chronic...  Equities.com1 month ago FDA grants Breakthrough designation to ibrutinib in cGVHD  European Pharmaceutical Review1 month ago

Health Canada Approves IMBRUVICA® (ibrutinib) for First-line Treatment of Chronic Lymphocytic Leukemia

IMBRUVICA®significantly improved progression-free, overall survival, and overall response rate versus an established chemotherapy TORONTO, July 20, 2016 The latest approval is based on data from the Phase 3 RESONATE-2 (PCYC-1115-CA) study, a ...
 Yahoo! Canada1 month ago Janssen receives Health Canada approval for Imbruvica to treat chronic lymphocytic leukaemia  PharmaBiz1 month ago BRIEF-Janssen says Health Canada approves Imbruvica for treatment of chronic lymphocytic leukemia  Reuters UK1 month ago The Changing Treatment Landscape of Chronic Lymphocytic Leukemia  CURE Magazine1 month ago

ArQule Presents Preclinical Data for ARQ 531, a Proprietary Reversible Inhibitor of Wild Type and Mutant BTK, at the 2016 Pan Pacific Lymphoma Conference

Data supports further preclinical and clinical research in BTK sensitive and ibrutinib resistant malignancies BURLINGTON, Mass., July 18, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced the first public presentation of data on ...
 4 Traders1 month ago

Ibrutinib and Idelalisib For CLL

onclivetv has 407 videos Subscribe Here Loading........ Video URL : Embed : Description: The mechanisms of ibrutinib and idelalisib for the treatment of chronic lymphocytic leukemia (CLL). Thomas Kipps, MD, PhD, Division of ...
 Oncology Tube2 weeks ago Ibrutinib, idelalisib, venetoclax provide very exciting developments in CLL  Healio1 month ago

Janssen's Imbruvica receives SMC recommendation for blood cancer treatment

The Scottish Medicines Consortium (SMC) has recommended pharmaceutical company Janssen's Imbruvica (ibrutinib) treatment for use in Scottish patients with specific types of rare and aggressive blood cancers. Ibrutinib is a new class of oral, ...
 CPhI.cn2 weeks ago First-in-class treatment now available for some patients in Scotland with rare, aggressive and incurable blood cancers  FirstWord Pharma2 weeks ago

Longer-Term Study Results From Phase III Studies of Ibrutinib in Patients with CLL/SLL

​ Longer-term follow-up results from phase III studies of Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) were recently announced. Findings include an analysis of outcomes from the RESONATE ...
 Oncology Times2 weeks ago Ibrutinib Shows Survival Benefit in Previously Treated CLL/SLL Patients with High-Risk Disease  ASH Clinical News4 weeks ago

Drug combinations in CLL: ibrutinib, ide...

Loading........ 38 views Description: Andrew Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, New York, NY discusses the mechanism of action of ibrutinib and idelalisib and further drug combinations under investigation in ...
 Oncology Tube3 weeks ago Trial of ibrutinib with bendamustine and rituximab in CLL: results and study design  Oncology Tube1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Ibrutinib
Get updated on latest news & your favorite topics right in your inbox!
More     Less